The authors (Gayathri Nagaraj, MD, and Cynthia X. Ma, MD, PhD) have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Nicole B. Harrold, BS, Manager, Continuing Education and Grants
Ms. Harrold has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Dowsett M, Allred C, Knox J et al.. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008;26:1059–1065.
- Search Google Scholar
- Export Citation
. Dowsett M Allred C Knox J Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008; 26: 1059– 1065.
Carlson RW, Allred DC, Anderson BO et al.. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3, 2012. Available at: NCCN.org. 2012. Accessed January 17, 2013.
Peto R, Davies C, Godwin J et al.. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–444.
Colleoni M, Gelber S, Coates AS et al.. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001;19:4141–4149.
Berry DA, Cirrincione C, Henderson IC et al.. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.
Hayes DF, Thor AD, Dressler LG et al.. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496–1506.
Mook S, Schmidt MK, Rutgers EJ et al.. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 2009;10:1070–1076.
Olivotto IA, Bajdik CD, Ravdin PM et al.. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716–2725.
Paik S, Shak S, Tang G et al.. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.
Paik S, Tang G, Shak S et al.. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.
Lo SS, Mumby PB, Norton J et al.. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671–1676.
van ‘t Veer LJ, Dai H, van de Vijver MJ et al.. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.
Mook S, Schmidt MK, Viale G et al.. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116:295–302.
Rouzier R, Perou CM, Symmans WF et al.. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678–5685.
Parker JS, Mullins M, Cheang MC et al.. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160–1167
Dowsett M, Lopez-Knowles E, Sidhu K et al.. Comparison of PAM50 risk of recurrence (ROR) score with Oncotype DX and IHC4 for predicting residual risk of RFS and distant-(D)RFS after endocrine therapy: a transATAC study. Cancer Res 2011;71(Suppl 3):S4–5.
Goldhirsch A, Wood WC, Coates AS et al.. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736–1747.